The AASLD – Liver Meeting 2019 – Boston, Massachusetts, USA
We have the pleasure to be present one more time at The AASLD Liver Meeting and talk about our scientific advances in the field of liver diseases through our four posters:
- Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients (0319)
- Additive effect of GNS561, a new lysosomotropic small molecule in combination with cisplatin or gemcitabine for the treatment of intrahepatic cholangiocarcinoma (0352)
- GNS561, a new oral clinical-stage small molecule combined with a PD-1 inhibitor showed remarkable anti-tumor effects in a transgenic immunocompetent hepatocellular carcinoma mouse model (ASV-B) (1993)
- GNS561, a new lysosomotropic small molecule, for the treatment of liver fibrosis (2143)
